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SMALL BOWEL TRANSPLANTATION 
Clinical Small Bowel or Small Bowel Plus Liver Transplantation Under 
FK506 
S. Todo, A. Tzakis, J. Reyes, K. Abu-Elmagd, A. Casavilla, B.M. Nour, R. Selby, J.J. Fung, D. Van Thiel, 
and T.E. Starzl 
As AN extension of multivisceral abdominal organ transplantation. I a clinical trial of intestinal trans-
plantation under FK 506 was instituted at the University 
Health Center of Pittsburgh in May 1990. From that time 
_ until the end of August 1991. nine patients received either 
an isolated small bowel graft (n = I) or combined smail 
bowel and liver grafts In = 8). The results as of May 1991 
in the initial five cases were reponed earlier this year.; We 
will describe here a 2·month longer follow-up of these five 
recipients and brief clinical notes on an additional four 
liver-intestinal transplantations. 
METHODS 
Case Material 
Three recipients were adults and 6 were children (Table I). All of 
the recipients had been mamtained preoperatively by total paren· 
teral nutrition (TPN) from 6 months to 4 1/3 years preoperatively. 
and had experienced life-threatening TPN-related complications 
repeatedly. Septic epIsodes had been seen in all of the recipients 
and eight had liver failure. Causes of the short-gut syndrome in the 
nine patients are listed in Table I. 
Operative Procedures 
Donor OperatIOn. Grafts were obtained from ABO-compatible 
ladavenc donors. of which two leases 5 and 9) had positive 
~ vtotoxic crossmatches with the recipients. The principles of the 
u~nor operation were described elsewhere.J Selective decontam-
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Table 1. Clinical Features of the 9 Patients 
Duration Transplantation 
Cause 01 Short-Gut olTPN Remallling Survival Current Grant 
Case Age Sex Syndrome (Months) Intestine Date Graft (Days) Function· Comments 
31.1 M Gun-shot wound 6 Transverse 5/2190 Small 486 Under treatment Chronie renal fail· 
colon-rectum bowel of rejection ure on dialysis 
2 2.3 F Necrotizing en· 3a Transverse 7/24190 Liver/small 403 Good 
terocolitis coion-rectum bowel 
3 26.7 F SMA thrombosis 30 Jejunum (20 em) 8/3190 LiverlSmall 393 Good Femoral arterial 
whole colon bowel graft 
4 4.3 M Gastroschisis 52 Jejunum (10 em) 11124190 Liver/small 280 Good Spinal cord injury 
whole colon bowel 
5 2.8 M Intestinal atresia 33 Transverse 3124191 Liver/small 159 Under treatment Respiratory sup-
coion-rectum bowel of rejection pan. ICU 
6 0.5 F Intestinal atresia 6 Transverse 8/9191 Liver/small 22 Under TPN In ICU 
colon-rectum bowel 
7 F Volvulus 12 Transverse 8/10/91 Liver/small 21 Under partial On floor 
colon-rectum bowel TPN 
8 1.5 F Volvulus 18 Jejunum (5 em) 8112191 Liver/small 19 UnderTPN InlCU 
whole colon bowel 
9 21 M Traffic accident 12 Transverse 8/21191 Liver/small 10 UnderTPN InlCU 
colon-rectum bowel 
'Follow-up 10 1 September 1. 
leu: intensMI care unrt. 
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inalion of the donor GI tract was attempted in all cases. Irradia-
tion or ALG administration to alter gnUt lymphoid tissues were 
not performed. The isolated intestinal graft was preserved by 
simple immersion in an ice bath without vascular Hushing. The 
liver and intestine grafts were cooled first by aortic infusion of 
University of Wisconsin (UW) solution (0.5 to I L). and subse-
quently by portal infusion of the liver with only U W solution ( I to 
2 L) on the back table. The intestinal lumen of the first three grafts 
was irrigated with cold-lactated Ringer's solution. while no such 
attempt was made with the last six grafts. The grafts were 
preserved from 3 to 10.5 hours. 
Recipient Operations. The surgical techniques were reported 
previouslyKl~ With liver-intestine transplantation. liver venous 
outftow was provided onto the intact retrohepatic inferior vena 
cava with the piggyback technique in seven recipients. and by the 
standard vena caval substitution method in one patient. Prior to 
the recipient hepatectomy. a portacaval shunt to decompress 
splanchnic venous congestion of the upper abdominal organs was 
performed in six cases. and retained permanently in two patients 
(cases 2 and 3). In the remaining six cases. the portacaval shunt 
was taken down after the transplantation was completed and the 
recipient portal vein was anastomosed to the side of graft portal 
vein. The intestine was vented at both ends by a chimney-type 
jejunostomy and ileostomy in the first five patients. but only by an 
ileostomy in the last four. The spleen had been removel . lone 
patient (case 2) before transplantation; three other patiellts had 
splenectomy during the operation because of splenic injury. 
PostoperatiVe Management 
Postoperative immunosuppression was with FK 506 and low-dose 
steroids as currently applied in our center for all organs,' except 
for a smaller continuous IV dose of FK 506 (0.1 mg/kg per day) 
than originally described. When enteral feeding became possible 
after 2 to 4 weeks. oral FK 506 was started at 0.3 mg/kg per day 
in divided doses. A low dose of Imuran (I to 2 mg/kg per day) was 
added in combination with FK 506 in patients 7 and 9 from the 
outset. Dose adjustments of FK 506 were strongly inHuenced by 
the quality of liver graft function.6 Histopathologic study of serial 
biopsies collected through the stomas or through a rectal endo-
scope was used to monitor intestinal graft rejection. 
TPN was continued during the immediate postoperative period 
and gradually reduced while enteral feeding was started after 2 to 
4 postoperative weeks. Selective decontamination was continued 
for 4 weeks while stool and blood cultures were carefully moni-
tored. 
Intestinal graft function was estimated principally by the 
amount and nature of stomal discharge, the ability to maintain 
body weight. serial serum protein analyses. D-xylose absorption 
results. and periodic G-I series. 
RESULTS 
Survival 
All of the 9 recipients are currently alive. The first 5 
patients have been foUowed for 4 to 15 months postoper-
atively. Two (patients 2 and 3) are at home and gaining 
weight without parenteral support. Two more were rehos-
pitalized recently for the treatment of graft rejection (pa-
tient 1), and for a medical complication (patient 4). Patient 
5 has been in the hospital continuously because of respi-
ratory insufficiency and recurrent rejection. The 4 recipi-
ents operated on at 1 to 3 weeks earlier are in the hospital. 
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Complications 
Postoperative complications in the first five recIpIents 
were renal failure (case I). femoral artery graft pseudoan-
eurysm at an arterial line insertion (case 3), and paraplegia 
secondary to a lumbar tap (case 4) which did not confirm 
suspected meningitis. The fifth patient has been on venti-
latory support because of paralysis of right hemidia-
phragma. which apparently occurred after injury of the 
phrenic nerve during the upper vena anastomosis. 
Rejection and Treatment 
The first five recipients experienced one to five episodes of 
intestinal graft rejection during the follow-up. Most rejec-
tions occurred during the initial hospitalization. and were 
treated mainly by FK 506 dose augmentation and. less 
frequently. by bolus steroid therapy. The most serious and 
persistent graft rejections were in the isolated smail bowel 
recipient (case 1) at .5. 5, and 14 postoperative months. 
and required steroid recycle treatment and OKT3 admin· 
istration. The last two episodes in this patient followed 
drug noncompliance after discharge. Prominent graft re-
jection was also seen in patient 5 at the fourth postopera-
tive month. soon after the reduction of immunosuppres-
sion for the management of a respiratory infection . 
The frequency and severity of hepatic graft rejection 
was similar to that in simple liver graft recipients. 
Graft versus host disease (GVRO) was not diagnosed in 
any patient. 
Bacterial Translocation 
Three of the first five recipients had a total of five bouts of 
bacterial translocation. as judged by bacteremia with the 
same organism found in the stool. One of these episodes 
only was associated with rejection. 
Graft Function 
The first five recipients were freed from TPN between 1.5 
and 9 months after transplantation. The patient who was 
TPN-dependent the longest was the isolated small bowel 
recipient. All but this patient (case I) gained body weight 
during the foUow-up and had normal absorption of D-XY-
lose. Currently, patients 2. 3, and 4 have normal intestinal 
function 13. 12, and 9 months after transplantation. respec-
tively. Patients I and 5 were placed back on TPN support 
because of late intestinal rejection after long periods of oral 
nutrition. 
DISCUSSION 
Experimental transplantation of the small bowel, as an 
isolated graft 7 or as a composite of multiple abdominal 
organs.s was described in dogs more than 30 years ago. 
However. compared to the progress of the other organ 
transplants during succeeding years, clinical small bowel 
transplantation under conventional immunosuppression 
has been unsatisfactory,9.lo except for isolated exam-
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pies. 11.12 Our experience suggests that small bowel trans-
~ plantation in humans could become more widely used. Our 
first four patients are either approaching or beyond the first 
postoperative year and three of them are healthy. The 
exceptional patient. an isolated small bowel recipient. had 
a stormy postoperative course and more vigorous graft 
rejection than most of the recipients of the small bowel 
plus liver. A simultaneously transplanted hepatic graft may 
protect the intestine from immunological attack as sug-
gested from the results of animal experiments. 13.14 and the 
pioneering observations of Wall et al 12 who were the first 
to succeed with clinical intestine-liver transplantation. 
A phenomenon seen previously in rats l4• IS and in all of 
our human recipients studied to date:' 16 was Iymphoretic-
ular repopulation. whereby these cells in the graft became 
those of the recipient. beginning within a few days after 
operation. What has happened to the lymphoreticular cells 
leaving the graft is under study and is of considerable 
- interest in connection with the late risk of GVHD. 
It is apparent that intestinal transplantation. alone or in 
combination with the liver. is a complex and hazardous 
undertaking. The good survival figures in our FK 506 
series tend to obscure the difficulties which one may 
expect as these trials proceed. The convalescence of all of 
our patients was difficult. requiring protracted hospitaliza-
tion. even if the operation was done successfully and there 
were no major complications. 
A total of 28 patients. 8 adults and 20 children. have 
been referred to our center during the last 15 months for 
small bowel (n = 5) or small bowel plus liver (n = 23) 
transplantation. They tended to be gravely ill when first 
seen. and 4 died of liver failure or sepsis while waiting. The 
9 who came to transplantation had protracted further 
dependence on TPN before their GI tract became free 
from ileus and was able to support oral nutrition. Yet. it 
seems clear that success can be expected in more than the 
isolated case. 
CONCLUSIONS 
Nine patients with the short-gut syndrome and liverfailure 
in eight cases were treated with isolated small bowel 
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transplantation (n = I) or smau bowel plus liver transplan-
tation (n = 8) under FK 506. All are alive after 10 days to 
15 months. In the first 5 recipients with the follow-up of 5 
to 15 months. TPN was discontinued between 1.5 and 9 
months postoperatively. Immunosuppression with FK 506 
appears to have been a significant factor in the improved 
outlook after intestinal transplantation. as was predicted 
from the prior demonstration of this drug's effectiveness in 
rats.14.17-19 
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